leadf
logo-loader
NASDAQ:AVCO

Avalon GloboCare Corp

Receive alerts
Market:
NASDAQ
Market Cap:
$91.28 m
Price
1.14 USD
Change
-0.87%
52 weeks high
2.50
52 weeks low
0.50

In brief

Avalon GloboCare Corp. (NASDAQ: AVCO) is a leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative exosome technologies and cellular therapeutics. Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients' growth, development, as well as competitiveness in both the domestic and global healthcare markets. Through its subsidiaries, namely GenExosome Technologies Inc. and Avactis Biosciences Inc., Avalon is establishing a leading role in the fields of exosome-based diagnostics (''liquid biopsy''), cellular immunotherapy (including CAR-T/CAR-NK), and regenerative medicine.

Snapshot

The company seeks to grow organically through old-fashion marketing efforts as well as via collaborations and partnerships, with a strong emphasis on China

Insight Widest with the analysis, Proactive gives perspectives that others don't.

Biopharmaceuticals battling COVID-19 pandemic to connect with investors via Proactive One2One Investor Forum on September 10

Shareholders and others will have the opportunity to engage with CEOs from AIM ImmunoTech, Heat Biologics, Avalon GloboCare, Oregenisis, and ImmunoPrecise Antibodies

on 9/9/20